GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease

People with type 2 diabetes experience greater improvements in glycaemic control when using Victoza®
New data from a study presented at the European Association for the Study of Diabetes (EASD) show a significantly higher proportion of patients reached the target for blood sugar control (HbA1c target <7%) when Victoza® (liraglutide [rDNA origin] injection) was administrated early in the treatment of type 2 diabetes to patients who had not received treatment before or previously only one oral anti-diabetic drug (OAD)....

Analyses find type 2 diabetes patients treated with BYDUREON™ experienced reduction in cardiovascular risk factors
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. have announced new analyses from the DURATION-3 and -4 trials demonstrating patients treated with the investigational medication BYDUREON™ (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments...

Lyxumia® (lixisenatide) one-step regimen as effective as two-step regimen in improving glycemic control in type 2 diabetes
Sanofi has announced that Lyxumia® (lixisenatide), a once-daily GLP-1 receptor agonist under development for type 2 diabetes, achieved its primary efficacy endpoint of significant HbA1c reduction vs. placebo in patients uncontrolled on metformin...

Lapatinib clinical trial update
A planned interim review of early data from ALTTO a Phase III, four arm study of adjuvant lapatinib (Tykerb/Tyverb®), trastuzumab, has resulted in a change to the ongoing study...

Abbott initiates international ABSORB BTK clinical trial for treatment of below-the-knee critical limb ischemia
Abbott has announced the initiation of ABSORB BTK, an international clinical trial evaluating the safety and efficacy of the ABSORB™ bioresorbable vascular scaffold (BVS) for the treatment of below-the-knee (BTK) critical limb ischemia...

PerkinElmer to acquire Caliper Life Sciences for approximately $600 million
PerkinElmer, Inc. has announced that it has signed a definitive agreement to acquire Caliper Life Sciences, Inc., a Hopkinton, Massachusetts-based leader in imaging and detection solutions for life sciences research, diagnostics and environmental markets...

Bristol-Myers Squibb completes acquisition of Amira Pharmaceuticals
Bristol-Myers Squibb Company has completed its previously announced acquisition of privately held Amira Pharmaceuticals, Inc...

Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year
Roche recognized as the most sustainable healthcare company globally in the DJSI for the third year in a row...

Novartis receives EU approval for Votubia®
The European Commission has approved Votubia® (everolimus) tablets* for the treatment of patients aged 3 years and older...